Gene therapy Archives

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 3 Oct 2022

Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics

LogicBio Therapeutics, Inc. has entered into a definitive agreement under which Alexion, AstraZeneca Rare Disease (Alexion) will acquire LogicBio. The proposed acquisition brings LogicBio’s technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion’s growth in genomic medicines. Fred Chereau, president and chief executive officer at LogicBio, said: “We are excited […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

More News! 29 Sep 2022

Removing binding sites for an oncogene can slow cancer cell growth, researchers say

Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […]

September 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Promising MND drug slows disease progression

Scientists in the U.K. believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care. Results from a phase 3 clinical trial showed significant physical benefits for patients after 12 months. Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) found that patients with a faulty SOD1 […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

Bioreactor platform launched to support process development for cell and gene therapy

A medical technology company, today announced the launch of a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector. Terumo Blood and Cell Technologies (Terumo BCT) named its Quantum Flex Cell Expansion System, after identifying the industry’s need for earlier automation to potentially limit additional and […]

September 20, 2022 - 3 minutesmins - By Liza Laws

In Depth 20 Sep 2022

Looming challenges for Europe’s cell and gene therapy space

The double whammy of Brexit and the COVID-19 pandemic have posed major logistical challenges for the development of cell and gene therapies (CGTs) in the last two years. In spite of these obstacles, Europe’s CGT market is catching up to that of the U.S. The CGT space experienced a shot in the arm in the […]

September 20, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 20 Sep 2022

CGT Catapult begins VR training to help ensure future workforce needs

A first-of-its-kind pilot to provide augmented reality (AR) and virtual reality (VR) training to develop the knowledge and skills needed for a career in advanced therapy medicinal product (ATMP) development has been launched. The training will be done by the Cell and Gene Therapy Catapult (CGT Catapult), in partnership with the University of Sheffield Advanced […]

September 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Sep 2022

New company formed to boost life sciences in Singapore

ClavystBio, a company established by CLA Real Estate Holdings, a wholly-owned subsidiary of Temasek, has launched, with its mission to accelerate the commercialization of life sciences discoveries and innovation in Singapore. The life sciences sector is set to be a key driver of Singapore’s future economy. The sector currently employs 25,000 workers and contributes to […]

September 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

SparingVision raises €75M for genomic medicines for ocular diseases

SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, has raised €75 million ($75 million) in series B financing. The round was co-led by Jeito Capital and UPMC Enterprises, with additional participation from 4BIO Capital, Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness, and Ysios Capital. Proceeds from the financing will […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Collaboration to explore gene therapy products for neurodegenerative disorders

Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […]

September 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Sep 2022

WhiteLab Genomics raises $10M for AI-powered genomic therapies platform

WhiteLab Genomics has announced the completion of a $10 million funding round. The round was led by French venture capital firm Omnes Capital, and Debiopharm, a Switzerland based biopharmaceutical company with a venture arm focused on digital health. WhiteLab Genomics said it aims to “revolutionize genomic therapy development” using public and private data and in-house […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

Interview 12 Sep 2022

Orchestrating the evolving cell therapy supply chain

In a few decades, the cell and gene therapy sector has diversified into many complex technologies. Paul Viggers, chief commercial officer at the U.K. firm TrakCel, explains how the company’s platform can tackle the intricacies of developing cell and gene therapies. After cell and gene therapy funding smashed records in 2021, the emerging sector has […]

September 12, 2022 - 5 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us